Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis

Alla Y. Grigorian, Houssam E. Mardini, Christophe Corpechot, Raoul Poupon, Cynthia Levy

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background and aim: Fenofibrate is a potential novel therapy for primary biliary cirrhosis (PBC). We performed a systematic review and a meta-analysis of studies of fenofibrate in PBC. Methods: Electronic database search was performed for relevant studies. A search of abstracts presented in the main scientific meetings in the field and articles in press was also performed. Random effect model was used to pool the effect size across studies for changes in alkaline phosphatase, GGT, bilirubin and IgM levels before and after treatment and the overall rate of complete response to fenofibrate therapy. Results: Six studies with 102 patients met the inclusion criteria. All studies were case series and in all, patients who had no or incomplete response to UDCA had fenofibrate added at a dose of 100-200. mg daily. Treatment duration ranged from 8-100. weeks. Treatment with fenofibrate was associated with a significant decrease in alkaline phosphatase (-114. IU/L, 95% CI: -152 to -76, P<. 0.0001); a significant decrease in GGT level (-92. IU/L, 95% CI: -149 to -43; P= 0.0004); significant decrease in total bilirubin (-0.11. mg/dL, 95% CI: -0.18 to -0.08; P= 0.0008); and a significant decrease in IgM level (-88. mg/dL, 95% CI: -119 to -58; P<. 0.0001). The complete response rate was 69% (95% CI: 53-82%) with an odds ratio of 82.8 (95% CI: 21.6-317.2; P= 0.024) while on fenofibrate. Conclusions: Fenofibrate at doses of 100-200. mg daily appears to be effective adjunctive therapy in PBC patients who had no or incomplete response to UDCA. There is a critical need for larger scale randomized trials to determine its effect on liver-related morbidity and mortality (or progression towards end-stage disease).

Original languageEnglish (US)
Pages (from-to)296-306
Number of pages11
JournalClinics and Research in Hepatology and Gastroenterology
Volume39
Issue number3
DOIs
StatePublished - Jun 1 2015

Fingerprint

Fenofibrate
Biliary Liver Cirrhosis
Meta-Analysis
Bilirubin
Therapeutics
Alkaline Phosphatase
Immunoglobulin M
Odds Ratio
Databases
Morbidity
Mortality
Liver

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis : A meta-analysis. / Grigorian, Alla Y.; Mardini, Houssam E.; Corpechot, Christophe; Poupon, Raoul; Levy, Cynthia.

In: Clinics and Research in Hepatology and Gastroenterology, Vol. 39, No. 3, 01.06.2015, p. 296-306.

Research output: Contribution to journalArticle

Grigorian, Alla Y. ; Mardini, Houssam E. ; Corpechot, Christophe ; Poupon, Raoul ; Levy, Cynthia. / Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis : A meta-analysis. In: Clinics and Research in Hepatology and Gastroenterology. 2015 ; Vol. 39, No. 3. pp. 296-306.
@article{89d6ef5f480f41e1907ccd9ebf944a98,
title = "Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis",
abstract = "Background and aim: Fenofibrate is a potential novel therapy for primary biliary cirrhosis (PBC). We performed a systematic review and a meta-analysis of studies of fenofibrate in PBC. Methods: Electronic database search was performed for relevant studies. A search of abstracts presented in the main scientific meetings in the field and articles in press was also performed. Random effect model was used to pool the effect size across studies for changes in alkaline phosphatase, GGT, bilirubin and IgM levels before and after treatment and the overall rate of complete response to fenofibrate therapy. Results: Six studies with 102 patients met the inclusion criteria. All studies were case series and in all, patients who had no or incomplete response to UDCA had fenofibrate added at a dose of 100-200. mg daily. Treatment duration ranged from 8-100. weeks. Treatment with fenofibrate was associated with a significant decrease in alkaline phosphatase (-114. IU/L, 95{\%} CI: -152 to -76, P<. 0.0001); a significant decrease in GGT level (-92. IU/L, 95{\%} CI: -149 to -43; P= 0.0004); significant decrease in total bilirubin (-0.11. mg/dL, 95{\%} CI: -0.18 to -0.08; P= 0.0008); and a significant decrease in IgM level (-88. mg/dL, 95{\%} CI: -119 to -58; P<. 0.0001). The complete response rate was 69{\%} (95{\%} CI: 53-82{\%}) with an odds ratio of 82.8 (95{\%} CI: 21.6-317.2; P= 0.024) while on fenofibrate. Conclusions: Fenofibrate at doses of 100-200. mg daily appears to be effective adjunctive therapy in PBC patients who had no or incomplete response to UDCA. There is a critical need for larger scale randomized trials to determine its effect on liver-related morbidity and mortality (or progression towards end-stage disease).",
author = "Grigorian, {Alla Y.} and Mardini, {Houssam E.} and Christophe Corpechot and Raoul Poupon and Cynthia Levy",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.clinre.2015.02.011",
language = "English (US)",
volume = "39",
pages = "296--306",
journal = "Clinics and Research in Hepatology and Gastroenterology",
issn = "2210-7401",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis

T2 - A meta-analysis

AU - Grigorian, Alla Y.

AU - Mardini, Houssam E.

AU - Corpechot, Christophe

AU - Poupon, Raoul

AU - Levy, Cynthia

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background and aim: Fenofibrate is a potential novel therapy for primary biliary cirrhosis (PBC). We performed a systematic review and a meta-analysis of studies of fenofibrate in PBC. Methods: Electronic database search was performed for relevant studies. A search of abstracts presented in the main scientific meetings in the field and articles in press was also performed. Random effect model was used to pool the effect size across studies for changes in alkaline phosphatase, GGT, bilirubin and IgM levels before and after treatment and the overall rate of complete response to fenofibrate therapy. Results: Six studies with 102 patients met the inclusion criteria. All studies were case series and in all, patients who had no or incomplete response to UDCA had fenofibrate added at a dose of 100-200. mg daily. Treatment duration ranged from 8-100. weeks. Treatment with fenofibrate was associated with a significant decrease in alkaline phosphatase (-114. IU/L, 95% CI: -152 to -76, P<. 0.0001); a significant decrease in GGT level (-92. IU/L, 95% CI: -149 to -43; P= 0.0004); significant decrease in total bilirubin (-0.11. mg/dL, 95% CI: -0.18 to -0.08; P= 0.0008); and a significant decrease in IgM level (-88. mg/dL, 95% CI: -119 to -58; P<. 0.0001). The complete response rate was 69% (95% CI: 53-82%) with an odds ratio of 82.8 (95% CI: 21.6-317.2; P= 0.024) while on fenofibrate. Conclusions: Fenofibrate at doses of 100-200. mg daily appears to be effective adjunctive therapy in PBC patients who had no or incomplete response to UDCA. There is a critical need for larger scale randomized trials to determine its effect on liver-related morbidity and mortality (or progression towards end-stage disease).

AB - Background and aim: Fenofibrate is a potential novel therapy for primary biliary cirrhosis (PBC). We performed a systematic review and a meta-analysis of studies of fenofibrate in PBC. Methods: Electronic database search was performed for relevant studies. A search of abstracts presented in the main scientific meetings in the field and articles in press was also performed. Random effect model was used to pool the effect size across studies for changes in alkaline phosphatase, GGT, bilirubin and IgM levels before and after treatment and the overall rate of complete response to fenofibrate therapy. Results: Six studies with 102 patients met the inclusion criteria. All studies were case series and in all, patients who had no or incomplete response to UDCA had fenofibrate added at a dose of 100-200. mg daily. Treatment duration ranged from 8-100. weeks. Treatment with fenofibrate was associated with a significant decrease in alkaline phosphatase (-114. IU/L, 95% CI: -152 to -76, P<. 0.0001); a significant decrease in GGT level (-92. IU/L, 95% CI: -149 to -43; P= 0.0004); significant decrease in total bilirubin (-0.11. mg/dL, 95% CI: -0.18 to -0.08; P= 0.0008); and a significant decrease in IgM level (-88. mg/dL, 95% CI: -119 to -58; P<. 0.0001). The complete response rate was 69% (95% CI: 53-82%) with an odds ratio of 82.8 (95% CI: 21.6-317.2; P= 0.024) while on fenofibrate. Conclusions: Fenofibrate at doses of 100-200. mg daily appears to be effective adjunctive therapy in PBC patients who had no or incomplete response to UDCA. There is a critical need for larger scale randomized trials to determine its effect on liver-related morbidity and mortality (or progression towards end-stage disease).

UR - http://www.scopus.com/inward/record.url?scp=84930872144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930872144&partnerID=8YFLogxK

U2 - 10.1016/j.clinre.2015.02.011

DO - 10.1016/j.clinre.2015.02.011

M3 - Article

C2 - 25882906

AN - SCOPUS:84930872144

VL - 39

SP - 296

EP - 306

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

IS - 3

ER -